Interleukin 31

ABBVI has also made waves with Zumalikibart's success in Phase 2 trials for atopic dermatitis.

By targeting the IL-31 pathway, this monoclonal antibody represents a new frontier in autoimmune disease treatment, showcasing the power of biologics to address intricate immune disorders.

Regulatory landscapes are shifting as well.

The U.S. Department of Health and Human Services SURPASS program aims to enhance trial efficiency through technological integration, a reflection of regulatory bodies' commitments to reducing costs and accelerating timelines.

Using a drug like dupilumab, tralokinumab, those are great for targeting a patient with, you know, just atopic dermatitis, and they may have a component of just hand eczema as well too.

So they are IL-13, IL-4, sometimes IL-31 driven.

The patient with CHE are a little bit different.

They're not just a Th2 driven disease.

And many patients will do great because that's what we did for years.

But now in this cohort of patients, I've had fantastic experience using nemolizumab, right? IL-31 I think is the most specific itch cytokine I find in my, in my hands treating like classic eczema.

It doesn't work as well or as fast for skin clearance.

Although, I mean, their clinical trial data show when you look six months, a year out, the patient's actual skin lesions from eczema do improve.

It's very fast.

Itch improvement kind of shuts it down.

And I'd say from a basic science perspective, I mean, IL-31 binds to the peripheral nervous system in terms of directly submitting these itch signals, right? But there is a particular enrichment of IL-31 receptors in the dorsal root ganglia.

So even if this is like a neuropathic process, like it can work in purely neuropathic itch, if there's that component of like, you know, immunosenescence, TH2 shift, it's working in that too.